iBio Announces Pricing of $50 Million Public Offering
1. iBio announced a public offering of pre-funded and Series G/H warrants. 2. The offering aims to raise approximately $50 million in gross proceeds. 3. Funds will support development of preclinical cardiometabolic programs. 4. Warrants are immediately exercisable and expire based on clinical milestones. 5. The offering is led by Leerink Partners and expected to close soon.